Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors

Study Description: The objective of this study is to understand the rate and extent of ocular involvement in COVID-19 patients and whether SARS-COV-2 can be detected in ocular fluids or tissue in convalescent phase. Objectives: Primary Objective: To investigate if COVID survivors show signs of anterior or posterior segment inflammation or other retinochoroidal changes after recovery. Secondary Objectives: To investigate if SARS-Cov-2 can be detected in the ocular fluids or tissues of survivors among patients who undergo medically indicated ocular surgery or diagnostic procedures. Exploratory Objective: To investigate whether the use of chloroquine/Hydroxychloroquine for treatment of COVID-19 is associated with ocular changes. Endpoints: Primary Endpoint: Percentage of patients with Ocular exam abnormalities such as conjunctival/corneal, anterior segment, choroidal, retinal lesions and subclinical findings on OCT, FA and ICG Secondary Endpoints: Correlation of ocular findings with COVID severity (by history) Proportion of patients with +SARS-COV-2 PCR in ocular fluid/tissues among COVID-19 survivors and correlation to clinical characteristics and IgG levels Study Population: Up to 150 COVID-19 survivors will be recruited. Description of Sites/Facilities Enrolling Participants: This protocol will enroll participants at the NIH CC. De-identified samples may be received from the New York Medical Center. Study Duration: 2 years Participant Duration: The participants will be asked to come to the NIH CC for one visit. A select subgroup of up to 75 participants with positive findings may be asked to return within 12 months from their initial visit.